Beijing Succeeder Technology Inc. Stock Analysis 688338.SS

Beijing Succeeder Technology, Inc. engages in the research, development, production and sale of detection instruments, reagents and consumables for thrombosis and hemostasis in the in-vitro diagnosis field. The company is headquartered in Beijing, Beijing and currently employs 255 full-time employees. The company went IPO on 2020-08-06. The firm primarily provides medical institutions with automated testing instruments for coagulation, hemorheology, hematocrit, and platelet aggregation, as well as supporting reagents and consumables. The Company’s main products include coagulation testers, hemorheology testers, and platelet aggregation testers. The Company’s products are primarily used in the prevention, screening, diagnosis, and monitoring of thrombotic and hemorrhagic diseases. The firm primarily operates in the domestic market.